Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer

The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD). The purpose of this project is to verify the therap

Trial Details

NCT ID
NCT06834321
Phase
PHASE2
Sponsor
baotai Liang
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Homoharringtonine combined with androgen deprivation therapy
  • Placebo combined with androgen deprivation treatment group
  • radical prostatectomy
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nantong, Jiangsu, China|32.03028,120.87472

Key Eligibility Criteria

  • ① Age ≥18 years and ≤85 years;
  • Histologically confirmed prostate cancer without small cell features;
  • Metastatic prostate cancer was identified by imaging examination with ≤5 oligometastases (bone or lymph node metastases) or cT3-4 stages; ④The scor…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →